STOCKSCOPE

Australian Shares Edge Higher as Inflation Risks and Global Technology Selloff Weigh on Sentiment

Mark Elzayed

Mark Elzayed

CIO at Vestra Capital

Published:23 Oct 2026
Australian Shares Edge Higher as Inflation Risks and Global Technology Selloff Weigh on Sentiment

Australian shares finished Friday marginally higher, with the S&P/ASX 200 gaining 0.02%, supported by Consumer Discretionary, Financials and Telecoms Services. However, underlying sentiment remained weak as investors assessed slowing domestic activity, persistent inflation and a global technology selloff. Market breadth reflected the caution, with 780 stocks declining, 319 advancing and 323 unchanged, while the S&P/ASX 200 VIX eased 0.42% to 11.11.

Consumer Stocks Lead Despite Widespread Selling

Temple & Webster (ASX: TPW) surged 32.92% to $5.41, leading the benchmark, while Nick Scali (ASX: NCK) advanced 4.66% to $12.59 and Premier Investments (ASX: PMV) gained 4.56% to $13.98.

Conversely, Zip Co (ASX: ZIP) plunged 29.71% to $1.46, while Capricorn Metals (ASX: CMM) declined 8.10% to $12.36. Liontown Resources (ASX: LTR) fell 7.61% to $0.64, reaching a 52-week low. We believe these sharp divergences highlight increasingly selective investor sentiment despite the benchmark's stability.

Bond Yields Retreat as RBA Inflation Concerns Persist

Australia's 10-year government bond yield slipped below 5.2%, reaching a seven-week low, as concerns surrounding artificial intelligence investment triggered safe-haven demand for bonds. The decline followed a US Treasury rally despite oil prices exceeding US$113 per barrel.

Meanwhile, a senior RBA official warned that inflation risks had deteriorated materially, partly reflecting elevated energy prices. Markets now assign a 64% probability of a 25-basis-point increase at the November 3 meeting, potentially the fifth hike this year. Next week's third-quarter inflation figures will be crucial in determining the monetary policy outlook.

Australian Business Activity Weakens Further

Australia's Services PMI declined to 47.8 in October from 51.9 in September, marking its first contraction since May and weakest reading since March. New business continued growing, although at a slower pace, while employment recovered following September's reductions.

Manufacturing remained subdued, with its PMI edging up to 49.7 from 49.6, marking a second consecutive contraction. New orders weakened, purchasing declined and delivery times deteriorated.

Both sectors reported accelerating energy, shipping, commodity and wage costs, prompting higher selling prices. We believe this combination of weakening demand and persistent inflation presents an increasingly difficult challenge for the RBA.

Asian and US Technology Shares Face Heavy Selling

China's Shanghai Composite dropped 1.5% to 3,602, while the Shenzhen Component lost 2.1% to 11,118, both reaching two-month lows. Semiconductor stocks led losses, including Cambricon Technologies (-3.7%), SMIC (-2.9%) and Eoptolink Technology (-6.1%), despite market-support efforts.

On Wall Street, the Nasdaq fell 2.6% and S&P 500 declined 1.21%, while the Dow gained 0.02%. Nvidia (-4.4%), AMD (-8.1%) and Micron (-6.3%) weakened as Meta Platforms' 7% decline followed plans for increased AI capital expenditure. US futures were subsequently little changed.

Oil Surges While Gold Faces Liquidation Pressure

Crude climbed above US$100 per barrel, approaching five-week highs amid Houthi attacks on Saudi infrastructure and reports of possible renewed US strikes against Iran. Despite tensions surrounding the Strait of Hormuz, Persian Gulf exports have recovered close to prewar levels, while Ukrainian attacks on Russian refineries added supply concerns.

Meanwhile, gold retreated towards US$4,000 an ounce, approaching three-month lows as investors liquidated holdings to cover equity losses. Higher oil prices reinforced inflation concerns, although reduced expectations for further Federal Reserve tightening could eventually support bullion.

Our Outlook: Remain Selective

We maintain a cautious to moderately bearish near-term outlook for Australian equities. Weakening business activity, persistent inflation and uncertainty surrounding AI investment suggest further volatility.

Nevertheless, we believe fundamentally strong companies with resilient earnings, manageable debt and pricing power could present opportunities as valuations adjust. Next week's inflation figures and the November RBA decision remain the immediate catalysts to watch.

Mark Elzayed

Mark Elzayed

(CIO at Vestra Capital)

Mark Elzayed is a prominent Australian financial executive and portfolio strategist with over a decade of hands-on capital markets experience. Having successfully managed over $100M+ in FUM across volatile economic cycles, Mark founded Vestra Capital to democratize institutional-grade quantitative strategies and privileged ASX deal flow for Australian investors.

DisclaimerInformation on Stockscope is general in nature and does not constitute financial product advice. It does not take into account your personal objectives, financial situation or needs. Seek independent advice from a qualified financial adviser before making an investment decision. Stockscope and its affiliates do not guarantee the accuracy or completeness of information published on this website. To the extent permitted by law, they accept no liability for any claim, loss or damage arising from its use or reliance on it. Stockscope and its associates may have commercial relationships with companies featured on this website, hold securities in those companies, or receive commissions in connection with capital raisings.

Continue Reading

ASX Weathers Wall Street's AI Rout, but Three Market Risks Are Becoming Harder to Ignore
Market Briefings
Market Briefings

ASX Weathers Wall Street's AI Rout, but Three Market Risks Are Becoming Harder to Ignore

Australian equities: what moved the ASX 200? Australian shares finished lower on Friday, 6 November, as the technology-led sell-off on Wall Street spread across global markets. The ASX 200...

Mark ElzayedMark Elzayed•
Epiminder (ASX: EPI) Expands FDA Clearance as $65 Million Cash Reserve Faces a Crucial Commercial Test
Biotech & Health
Biotech & Health

Epiminder (ASX: EPI) Expands FDA Clearance as $65 Million Cash Reserve Faces a Crucial Commercial Test

Epiminder Limited ASX: EPI has expanded the US market for its epilepsy monitoring technology following a significant regulatory clearance, strengthening its commercial prospects ahead of a p...

Danny AadDanny Aad•
Asara Resources (ASX: AS1) Hits 38m at 2.1g/t Gold: Could Sogosogoba Unlock Kada's Next Growth Phase?
Mining
Mining

Asara Resources (ASX: AS1) Hits 38m at 2.1g/t Gold: Could Sogosogoba Unlock Kada's Next Growth Phase?

A 38-metre gold intersection grading 2.1 grams per tonne has given Asara Resources Limited ASX: AS1 an encouraging exploration result beyond its established Massan deposit in Guinea. The dis...

Alison ElzayedAlison Elzayed•
Alvo Minerals (ASX: ALV) Expands Rare Earth Discovery Across 6.5km², but Can It Deliver Economic Value?
Mining
Mining

Alvo Minerals (ASX: ALV) Expands Rare Earth Discovery Across 6.5km², but Can It Deliver Economic Value?

Alvo Minerals Limited ASX: ALV has extended rare earth mineralisation approximately 2 kilometres beyond previously tested areas at its Boa Vista prospect in Brazil, strengthening the explora...

Alison ElzayedAlison Elzayed•
Avenira Limited (ASX: AEV) Raises $48.9 Million as Wonarah Phosphate Project Faces Its Biggest Test Yet
Mining
Mining

Avenira Limited (ASX: AEV) Raises $48.9 Million as Wonarah Phosphate Project Faces Its Biggest Test Yet

Avenira Limited ASX: AEV has reached a significant financing milestone, with its $48.9 million rights issue providing fresh capital to advance the Wonarah Phosphate Project in the Northern T...

Alison ElzayedAlison Elzayed•
Mayne Pharma Group (ASX: MYX) Unveils $55.5 Million Sale, but Can Its US Business Deliver Stronger Profits?
Biotech & Health
Biotech & Health

Mayne Pharma Group (ASX: MYX) Unveils $55.5 Million Sale, but Can Its US Business Deliver Stronger Profits?

Mayne Pharma Group Limited ASX: MYX is taking a decisive step towards becoming a US-focused pharmaceutical company, agreeing to sell its international operations for $55.5 million. The tran...

Danny AadDanny Aad•
Loading more stories...